Frontiers in cancer immunotherapy-a symposium report

Cable Jennifer; Greenbaum Benjamin; Peer Dana; Bollard Catherine M.; Bruni Sofia; Griffin Matthew E.; Allison James P.; Wu Catherine J.; Subudhi Sumit K.; Mardis Elaine R.; Brentjens Renier; Sosman Jeffry A.; Cemerski Saso; Zavitsanou Anastasia-Maria; Proia Theresa; Egeblad Mikala; Nolan Garry; Goswami Sangeeta; Spranger Stefani; Mackall Crystal L.

首页> 外文期刊>Annals of the New York Academy of Sciences >Frontiers in cancer immunotherapy-a symposium report

【24h】

Frontiers in cancer immunotherapy-a symposium report

机译：癌症免疫疗法的前沿 - 一个研讨会报告

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Cancer immunotherapy has dramatically changed the approach to cancer treatment. The aim of targeting the immune system to recognize and destroy cancer cells has afforded many patients the prospect of achieving deep, long-term remission and potential cures. However, many challenges remain for achieving the goal of effective immunotherapy for all cancer patients. Checkpoint inhibitors have been able to achieve long-term responses in a minority of patients, yet improving response rates with combination therapies increases the possibility of toxicity. Chimeric antigen receptor T cells have demonstrated high response rates in hematological cancers, although most patients experience relapse. In addition, some cancers are notoriously immunologically "cold" and typically are not effective targets for immunotherapy. Overcoming these obstacles will require new strategies to improve upon the efficacy of current agents, identify biomarkers to select appropriate therapies, and discover new modalities to expand the accessibility of immunotherapy to additional tumor types and patient populations.

机译：癌症免疫疗法大大改变了癌症治疗方法。针对免疫系统识别和破坏癌细胞的目的是，许多患者提供了深入，长期缓解和潜在治疗的前景。然而，对于实现所有癌症患者的有效免疫疗法的目标，仍然存在许多挑战。检查点抑制剂已经能够在少数患者中达到长期反应，但随着组合疗法的改善率提高了毒性的可能性。嵌合抗原受体T细胞在血液癌中表现出高响应率，尽管大多数患者经历复发。此外，一些癌症是惊人的免疫学“冷”，通常是免疫疗法的无效目标。克服这些障碍需要新的策略来改善当前剂的疗效，鉴定生物标志物选择适当的疗法，并发现新的方式扩展免疫疗法的可达性与额外的肿瘤类型和患者群体。

著录项

来源
《Annals of the New York Academy of Sciences》 |2021年第4期|30-47|共18页
作者
Cable Jennifer; Greenbaum Benjamin; Peer Dana; Bollard Catherine M.; Bruni Sofia; Griffin Matthew E.; Allison James P.; Wu Catherine J.; Subudhi Sumit K.; Mardis Elaine R.; Brentjens Renier; Sosman Jeffry A.; Cemerski Saso; Zavitsanou Anastasia-Maria; Proia Theresa; Egeblad Mikala; Nolan Garry; Goswami Sangeeta; Spranger Stefani; Mackall Crystal L.;
展开▼
作者单位

PhD Sci Writer New York NY USA;

Mem Sloan Kettering Canc Computat Oncol Program Computat Immunooncol Dept Epidemiol & Biostat New York NY USA;

Mem Sloan Kettering Canc Parker Inst Canc Immunotherapy Program Computat & Syst Biol New York NY USA|Mem Sloan Kettering Canc Ctr Parker Inst Canc Immunotherapy New York NY USA;

George Washington Univ Natl Childrens Hosp Ctr Canc & Immunol Res Washington DC USA;

Consejo Nacl Invest Cient & Tecn IBYME Lab Mol Mech Carcinogenesis Buenos Aires DF Argentina;

Rockefeller Univ New York Lab Chem Biol & Microbial Pathogenesis New York NY USA;

Univ Texas MD Anderson Canc Ctr Immunotherapy Platform Houston TX 77030 USA|Univ Texas MD Anderson Canc Ctr Dept Immunol Houston TX 77030 USA;

Dana Farber Canc Inst Dept Med Oncol Boston MA 02115 USA|MIT Broad Inst 77 Massachusetts Ave Cambridge MA 02139 USA|Harvard Univ Cambridge MA 02138 USA|Harvard Med Sch Boston MA 02115 USA|Brigham & Womens Hosp Dept Med 75 Francis St Boston MA 02115 USA;

Univ Texas MD Anderson Canc Ctr Dept Genitourinary Med Oncol Houston TX 77030 USA;

Nationwide Childrens Hosp Rasmussen Inst Genom Med Columbus OH USA;

Mem Sloan Kettering Canc Ctr Dept Med & Ctr Cell Engn 1275 York Ave New York NY 10021 USA;

Northwestern Univ Div Hematol & Oncol Dept Med Feinberg Sch Med Chicago IL 60611 USA;

Cue Biopharma Cambridge MA USA;

NYU Sch Med Dept Pathol New York NY USA;

AstraZeneca Waltham MA USA;

Canc Ctr Cold Spring Harbor Lab New York NY USA;

Stanford Univ Baxter Lab Stem Cell Biol Stanford CA 94305 USA|Stanford Univ Dept Microbiol & Immunol Stanford CA 94305 USA|Parker Inst Canc Immunotherapy San Francisco CA USA;

Univ Texas MD Anderson Canc Ctr Dept Genitourinary Med Oncol Houston TX 77030 USA;

MIT Koch Inst Integrat Canc Res 77 Massachusetts Ave Cambridge MA 02139 USA|MIT Dept Biol 77 Massachusetts Ave Cambridge MA 02139 USA;

Stanford Canc Inst Ctr Canc Cell Therapy Stanford CA USA|Stanford Univ Dept Pediat Sch Med Stanford CA 94305 USA|Stanford Univ Dept Med Sch Med Stanford CA 94305 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
cancer vaccine; CAR T; checkpoint inhibitors; immune evasion; immuno#8208; oncology; immunogenomics; immunotherapy; neoantigen; T cell therapy; tumor microenvironment;

机译：癌症疫苗;汽车T;检查点抑制剂;免疫逃避;免疫肿瘤学;免疫疗法;免疫疗法;Neoantigen;T细胞疗法;肿瘤微环境;肿瘤微环境;肿瘤微环境;肿瘤微环境;

Frontiers in cancer immunotherapy-a symposium report

摘要

著录项

相关主题

期刊订阅